0.10Open0.10Pre Close0 Volume1 Open Interest10.00Strike Price0.00Turnover125.47%IV68.90%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier30DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1102Delta0.0868Gamma59.80Leverage Ratio-0.0067Theta0.0005Rho6.59Eff Leverage0.0033Vega
MeiraGTx Holdings Stock Discussion
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
MeiraGTx Holdings plc (Nasdaq: MGTX) announced five poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress in Rome, Italy. The posters highlight the company's advancements in genetic medicine and cell therapy platforms:
1. Optimized AAV manufacturing platform yielding high titers and improved product quality.
2....
MeiraGTx Holdings | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Johnson & Johnson(8.6%),Johnson & Johnson Innovation-JJDC, Inc.(8.6%)
MeiraGTx Holdings PLC: Primary Study Objective of Safety and Tolerability Was Met
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi -4/sh
MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical stage genetic medicine company, has announced the pricing of an underwritten offering of 12,500,000 ordinary shares at $4.00 per share. The offering, expected to close on August 13, 2024, aims to raise $50 million in gross proceeds. Sanofi led the financing with a $30 million equity investment, joined by Perceptive Advisors and other inst...
Dow Jones· just
No comment yet